Briacell Therapeutics Corp. - Common Shares (BCTX) closed at $3.95 on November 6, 2026, up 20.8% from the previous close, on volume of 156,007 shares (30-day average 75,354).
Data as of November 6, 2026.
BriaCell Reports Broad Preclinical Immunotherapy Activity at SITC
TipRanks (Fri, 6-Nov 10:05 AM ET)
Globe Newswire (Fri, 6-Nov 9:00 AM ET)
BriaCell Awarded 2026 'Immunotherapy Solution of the Year' By BioTech Breakthrough
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
BriaCell and BriaPro Present Preclinical Immunotherapy Data
TipRanks (Tue, 3-Nov 11:14 AM ET)
Globe Newswire (Tue, 3-Nov 9:00 AM ET)
Globe Newswire (Fri, 23-Oct 7:30 AM ET)
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Globe Newswire (Tue, 6-Oct 7:30 AM ET)
Globe Newswire (Mon, 14-Sep 7:30 AM ET)
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
Globe Newswire (Fri, 11-Sep 8:45 AM ET)
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.
As of November 6, 2026, BCTX stock price climbed to $3.95 with 156,007 million shares trading.
BCTX has a beta of 1.80, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.05 to the broad based SPY ETF.
BCTX has a market cap of $34.49 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BCTX traded as high as $895.50 and as low as $2.60.
BCTX has underperformed the market in the last year with a return of -59.8%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BCTX shares. However, BCTX has outperformed the market in the last 3 month and 2 week periods, returning +14.5% and +15.0%, while SPY returned -4.1% and -3.2%, respectively. This indicates BCTX has been having a stronger performance recently.
BCTX support price is $3.08 and resistance is $3.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.
